Modifier genes may account for the phenotypic variability observed in the late-onset forms of globoid cell leukodystrophy (GCL) in humans. In order to begin a search for modifier genes, the effect of genetic background on the clinical and pathological manifestations of GCL was investigated in twitcher mice. Twitcher mice on a C57BL/6 ؋ CAST/Ei background had an increased life span (61.4 ؎ 2.5 vs 37.0 ؎ 0.6 days), a delayed onset of tremor (24 vs 21 days), and a delayed decline in walking ability compared to C57BL/6 twitcher mice. Pathologically, C57BL/6 ؋ CAST/Ei twitcher mice had fewer lectin-positive globoid cells, less gliosis, and a greater preservation of myelin compared to C57BL/6 twitcher mice under moribund conditions. Similar concentrations of psychosine, the toxic species that accumulates in GCL, were measured by tandem mass spectrometry between moribund C57BL/6 twitcher mice (286.5 pmol/mg protein), 40-day C57BL/6 ؋ CAST/Ei twitcher mice (276.5 pmol/mg), and moribund C57BL/6 ؋ CAST/Ei twitcher mice (247.0 pmol/mg), suggesting that the milder phenotype in CAST/Ei ؋ C57BL/6 twitcher mice did not correlate with less psychosine. In summary, the introduction of modifier genes from the wild, inbred CAST/Ei strain had a phenotypic effect resulting in a significantly slower disease course.
INTRODUCTION
Globoid cell leukodystrophy (GCL) is an autosomal recessive disorder caused by mutations in the gene encoding for the lysosomal enzyme galactosylceramidase. This enzyme catalyzes the first step in the degradation of galactosylceramide, a major glycolipid of central and peripheral myelin, and psychosine, a secondary product of UDP-galactosylceramide galactosyltransferase, which also synthesizes galactosylceramide. A deficiency of galactosylceramidase leads to the progressive accumulation of psychosine in the brain and kidney (Miyataki & Suzuki 1972; Svennerholm et al., 1980; Igisu & Suzuki 1984) . Psychosine is toxic to a variety of cells (Igisu, 1989; Tapasi et al., 1998) and it has been postulated to cause early pathological changes in oligodendrocytes and Schwann cells (Tanaka & Webster 1993; Cho et al., 1997) that eventually lead to extensive demyelination.
The onset of clinical signs in patients with GCL is variable. The infantile form has an onset within the first 6 months of life, the late infantile form presents from 6 months to 3 years, the juvenile form appears from 3 to 10 years, and the adult variant has symptoms beginning after 10 years (Kolodny et al., 1991; Wenger et al., 2001) . In the infantile form of disease there is Յ5% of the normal levels of galactosylceramidase (Luzi et al., 2001) , while the residual enzyme activity is slightly higher in the later onset forms of disease (Krivit et al., 1995; De Gasperi et al., 1996 , 1999 Jardim et al., 1999) . Expression studies have identified alleles that result in a lowering of enzymatic activity below median normal levels (Furuya et al., 1997) . For example, a substitution of cysteine by histidine at a.a. 
